120.76
2.85%
-3.54
Dopo l'orario di chiusura:
121.00
0.24
+0.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché NVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Novo Nordisk Adr Borsa (NVO) Ultime notizie
Novo Nordisk ADR (NVO) Stock: A Year of Decreases and Increases - The InvestChronicle
3 Stocks That Could Rise on European Bank Interest Rate Cuts - Benzinga
Novo Nordisk Slips On Analyst Warning Of Weaker Wegovy Sales - Investor's Business Daily
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy? - The Motley Fool
Prediction: Eli Lilly Will Dominate the Billion-Dollar Weight Loss Drug Market for This Key Reason - The Motley Fool
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development - Benzinga
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why. - The Motley Fool
Eli Lilly Stock: Is LLY Stock A Buy After Snagging Approval For A New Eczema Drug? - Investor's Business Daily
Analysts review Novo Nordisk ADR’s rating - Knox Daily
DexCom Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen' - Benzinga
Why This Stock Could Be the Nvidia of Healthcare - The Motley Fool
Wall Street Analyst Initiated Novo Nordisk ADR [NVO]. What else is Wall St. saying - The DBT News
Balance Sheet Insights: Novo Nordisk ADR (NVO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk? - Morningstar
Novo Nordisk ADR (NVO) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
European Equities Traded in the US as American Depositary Receipts Decrease Friday - MSN
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today - The Motley Fool
Novo Dives — And Corbus Crashes — On Psychiatric Side Effects Of Weight-Loss Drug - Investor's Business Daily
Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients - Benzinga
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure - Benzinga
Novo Nordisk ADR (NVO)’s Day in Review: Closing at 132.06, Up by 0.05 - The Dwinnex
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks - The Motley Fool
Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications - Benzinga
Understanding the Risks of Investing in Novo Nordisk ADR (NVO) - Knox Daily
Novo Nordisk ADR Inc. (NVO) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments - The Motley Fool
Novo Nordisk ADR Sees Its Composite Rating Rise To 96 - Investor's Business Daily
Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo Finance
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now. - The Motley Fool
Should You Invest in This Under-the-Radar Weight Loss Stock? - The Motley Fool
2 Unstoppable Healthcare Stocks to Buy Right Now for Less Than $200 - The Motley Fool
Why Investors Plowed Into Viking Therapeutics Stock Today - The Motley Fool
NVO: With Obesity Drug Demand Surging, Is Novo Nordisk a Buy? - StockNews.com
Market Analysts see Novo Nordisk ADR [NVO] gaining to $156. Time to buy? - The DBT News
Why Roche Holdings Stock Withered on Wednesday - The Motley Fool
Novo Jumps After Weight-Loss Pill Tops Wegovy; Lilly, Viking Shares Rise - Investor's Business Daily
Can Novo Nordisk ADR Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy - Benzinga
Is Hims & Hers Health the Next Teladoc? - The Motley Fool
This Unstoppable Stock Has Gained 100,203% Over The Last 50 Years, Creating Many Millionaires in the Process. Here Are 3 Reasons I Think It Will Continue to Create Generational Wealth. - The Motley Fool
Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead? - The Motley Fool
Novo Nordisk ADR [NVO] Stock trading around $130.89 per share: What’s Next? - The DBT News
This Big Move by Eli Lilly May Solve the Weight Loss Drug Market's Biggest Problem - The Motley Fool
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts - Benzinga
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern - Benzinga
Battle Over Compounded Weight-Loss Medications - Benzinga
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know. - The Motley Fool
Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors? - The Motley Fool
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race - Benzinga
The Best Biotech Stock to Invest $1,000 in Right Now - The Motley Fool
2 Big Risks and 2 Big Opportunities for Ginkgo Bioworks Stock - The Motley Fool
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now - The Motley Fool
Judge's Early Ruling May Shape Outcome In Ozempic, Wegovy Lawsuits - Benzinga
Experts predict Novo Nordisk ADR’s (NVO) current quarter earnings growth rate - US Post News
How does Novo Nordisk ADR (NVO) change from a tortoise to a hare? - SETE News
Novo Nordisk Touts Encouraging Wegovy Data To Lower Risk Of Severe Complications In Heart Failure Patients - Benzinga
Novo Nordisk's Massive GLP-1 Growth Reflects the Firm's Wide Moat in Cardiometabolic Diseases - Morningstar
This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock - The Motley Fool
Global GLP-1 Analogues Market Report 2024-2032: Market Expansion Driven by Innovation and Efficacy in Diabetes and Obesity Treatment - GlobeNewswire Inc.
Novo Nordisk ADR (NVO) Stock: From Low to High in 52 Weeks - The InvestChronicle
Should Novo Nordisk ADR (NYSE: NVO) Investors Be Concerned? - Stocks Register
Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble? - The Motley Fool
2 No-Brainer Healthcare Stocks to Buy With $1,000 - The Motley Fool
Perhaps timely catching Novo Nordisk ADR (NVO) would be a good idea - SETE News
NVO’s Market Whiplash: 29.57% YTD Rise, 0.57% Rise in 30 Days - The InvestChronicle
ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing - GlobeNewswire Inc.
Eli Lilly Stock Could Soar to $1,150, According to a Wall Street Analyst. Is It a Buy at Around $945? - The Motley Fool
Why Eli Lilly Topped the Market on Tuesday - The Motley Fool
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons - GlobeNewswire Inc.
Hemophilia Market Size to Surpass US$ 23.99 Billion by 2033, The Brainy Insights - GlobeNewswire Inc.
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons - GlobeNewswire
Novo Nordisk A/Sshare repurchase programme - GlobeNewswire
Prediction: These 2 Unstoppable Pharma Stocks Will Continue to Soar Through 2025 and Beyond - The Motley Fool
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):